Related Experiment Video
Updated: Jul 13, 2025

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
Published on: May 12, 2023
An Embarrassment of Riches: Three FDA-Approved Bispecific Antibodies for Relapsed Refractory Multiple Myeloma
Ross Firestone1, Alexander M Lesokhin1, Saad Z Usmani1
1Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Summary:
In the past year, three new bispecific antibodies have received accelerated FDA approval for the treatment of relapsed/refractory multiple myeloma. In this article, we review the available data for these three agents, teclistamab, elranatamab, and talquetamab, and discuss practical considerations for their use in clinical settings while the medical community awaits randomized phase III clinical trial datasets comparing them to standard-of-care regimens.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Hybridoma Technology
Hybridoma Selection
Commonly used fusion techniques — electroporation,...

